Investor Presentation Q1-Q3 2020

20 Investor presentation First nine months of 2020 Diabetes care Strengthen leadership by offering innovative medicines and driving patient outcomes Novo Nordisk Way Obesity care Strengthen treatment options through market development and by offering innovative medicines and driving patient outcomes Biopharm Secure a leading position by leveraging full portfolio and expanding into adjacent areas Driving change to defeat diabetes and other serious chronic diseases Sustainable business Other serious chronic diseases Establish presence by building competitive pipeline and scientific leadership

View entire presentation